Needle-free jet injection of DNA and protein vaccine of the Far-Eastern subtype of tick-borne encephalitis virus induces protective immunity in mice

Omori-Urabe, Yuki; Yoshii, Kentaro; Ikawa-Yoshida, Ayae; Kariwa, Hiroaki; Takashima, Ikuo

doi:10.1111/j.1348-0421.2011.00389.x

Cited by 9 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 and Table 1 ). These results are not consistent with the findings of groups reporting that DSJI do not significantly improve the immunogenicity of the plasmid DNA vaccine over needle and syringe [26], but are consistent with other groups reporting enhanced immunogenicity [27-29]. …”

Section: Discussioncontrasting

confidence: 99%

A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates

Kwilas¹,

Kishimori²,

Josleyn³

et al. 2014

CGT

View full text Add to dashboard Cite

Sin Nombre virus (SNV) and Andes virus (ANDV) cause most of the hantavirus pulmonary syndrome (HPS) cases in North and South America, respectively. The chances of a patient surviving HPS are only two in three. Previously, we demonstrated that SNV and ANDV DNA vaccines encoding the virus envelope glycoproteins elicit high-titer neutralizing antibodies in laboratory animals, and (for ANDV) in nonhuman primates (NHPs). In those studies, the vaccines were delivered by gene gun or muscle electroporation. Here, we tested whether a combined SNV/ANDV DNA vaccine (HPS DNA vaccine) could be delivered effectively using a disposable syringe jet injection (DSJI) system (PharmaJet, Inc). PharmaJet intramuscular (IM) and intradermal (ID) needle-free devices are FDA 510(k)-cleared, simple to use, and do not require electricity or pressurized gas. First, we tested the SNV DNA vaccine delivered by PharmaJet IM or ID devices in rabbits and NHPs. Both IM and ID devices produced high-titer anti-SNV neutralizing antibody responses in rabbits and NHPs. However, the ID device required at least two vaccinations in NHP to detect neutralizing antibodies in most animals, whereas all animals vaccinated once with the IM device seroconverted. Because the IM device was more effective in NHP, the Stratis® (PharmaJet IM device) was selected for follow-up studies. We evaluated the HPS DNA vaccine delivered using Stratis® and found that it produced high-titer anti-SNV and anti-ANDV neutralizing antibodies in rabbits (n=8/group) as measured by a classic plaque reduction neutralization test and a new pseudovirion neutralization assay. We were interested in determining if the differences between DSJI delivery (e.g., high-velocity liquid penetration through tissue) and other methods of vaccine injection, such as needle/syringe, might result in a more immunogenic DNA vaccine. To accomplish this, we compared the HPS DNA vaccine delivered by DSJI versus needle/syringe in NHPs (n=8/group). We found that both the anti-SNV and anti-ANDV neutralizing antibody titers were significantly higher (p-value 0.0115) in the DSJI-vaccinated groups than the needle/syringe group. For example, the anti-SNV and anti-ANDV PRNT50 geometric mean titers (GMTs) were 1,974 and 349 in the DSJI-vaccinated group versus 87 and 42 in the needle/syringe group. These data demonstrate, for the first time, that a spring-powered DSJI device is capable of effectively delivering a DNA vaccine to NHPs. Whether this HPS DNA vaccine, or any DNA vaccine, delivered by spring-powered DSJI will elicit a strong immune response in humans, requires clinical trials.

show abstract

Section: Discussioncontrasting

confidence: 99%

A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates

Kwilas¹,

Kishimori²,

Josleyn³

et al. 2014

CGT

View full text Add to dashboard Cite

show abstract

“…Mice immunized intramuscularly by a needle-free jet injector developed a greater VN antibody response than after subcutaneous vaccination with needle-syringe injection, albeit lower amounts of DNA were used for needle-free immunization. The wide dispersion and therefore enhanced uptake of DNA after needle-free administration most likely account for this difference [ 207 ]. Using nucleic-acid vaccines, the biochemical delivery method and use of adjuvants influence vaccine-induced immunity, too (reviewed in [ 208 , 209 ]).…”

Section: Novel Approaches and Tbev Target Antigens For The Developmentioning

confidence: 99%

Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise

et al. 2020

View full text Add to dashboard Cite

Tick-borne encephalitis virus (TBEV), a member of the family Flaviviridae, is one of the most important tick-transmitted viruses in Europe and Asia. Being a neurotropic virus, TBEV causes infection of the central nervous system, leading to various (permanent) neurological disorders summarized as tick-borne encephalitis (TBE). The incidence of TBE cases has increased due to the expansion of TBEV and its vectors. Since antiviral treatment is lacking, vaccination against TBEV is the most important protective measure. However, vaccination coverage is relatively low and immunogenicity of the currently available vaccines is limited, which may account for the vaccine failures that are observed. Understanding the TBEV-specific correlates of protection is of pivotal importance for developing novel and improved TBEV vaccines. For affording robust protection against infection and development of TBE, vaccines should induce both humoral and cellular immunity. In this review, the adaptive immunity induced upon TBEV infection and vaccination as well as novel approaches to produce improved TBEV vaccines are discussed.

show abstract

“…-рекомбинантные вакцины, представляющие вирионные белки пре-М + Е [31], фрагмент поверхностного гликопротеина Е, иммобилизованный на декстрансульфате в сочетании с олигонуклеотидами CpG [32], или неструктурный белок NS1 [33,34] в виде ДНК-вакцин или в составе разных векторов;…”

Section: новые подходы к созданию вакцины для защиты против кэunclassified

“…(п.п. 1, 2, 4, 5, 8-11, 13, 16, 17, 20, 28, 30-51 протеины пре-М и Е, полученные в бактериальных системах [31], дрожжах [35] и клетках млекопитающих [36,37]; -живые аттенуированные вакцины с мутациями в разных участках генома, в первую очередь в нетранслируемых областях или с делецией в белке нуклеокапсида С [38][39][40][41], а также полученные с помощью рандомизированного кодирования кодонов в сочетании с обратной генетикой без использования бактерий [42];…”

Section: заключениеunclassified

“…Эффективность одноразовой иммунизации в экспериментах на лабораторных мышах для защиты от дальневосточного подтипа вируса КЭ была показана для ДНК вакцины, несущей гены пре-М и Е [31], а также для самореплицирующейся неинфекционной РНК [46].…”

Section: л и т е рат у раunclassified

See 1 more Smart Citation

On Modern Approaches to Creation of a Single-Cycle Vaccine Against Tick-Borne Encephalitis

Lashkevich

Karganova

2018

Problems of Virology

View full text Add to dashboard Cite

In Russia, about 2000 people get tick-borne encephalitis (TBE) every year. Almost none of them are vaccinated. For the prevention of TBE, inactivated vaccines (IVTBE) are used. IVTBE are safe and protect from TBE not less than 95% of vaccinated. The disadvantages of IVTBE are the need for numerous intramuscular injections by medical personnel, the high cost of vaccination and the vaccination refusals. A new vaccine against TBE should not be inferior to IVTBE in its safety and efficacy, should cause long-term immunity after a single application, and, preferably, be effective after oral administration. Currently, genetic engineering methods for producing replication-defective (single-cycle) flaviviruses that can serve as the basis for creating new types of safe vaccines similar in many characteristics to classic live vaccines based on attenuated strains of viruses have been proposed. The possibility of infecting humans with TBE by the use of milk of naturally infected animals, as well as the experience of using experimental live TBE vaccines, are prerequisites for the creation of a safe oral single-dose TBE vaccine.

show abstract

Needle-free jet injection of DNA and protein vaccine of the Far-Eastern subtype of tick-borne encephalitis virus induces protective immunity in mice

Cited by 9 publications

References 19 publications

A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates

A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates

Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise

On Modern Approaches to Creation of a Single-Cycle Vaccine Against Tick-Borne Encephalitis

Contact Info

Product

Resources

About